Application of sRNA of traditional Chinese medicine source and vector of sRNA in preparation of broad-spectrum antiviral drugs
Through high-throughput sequencing and construction of overexpression plasmids, the sRNA sequences in beef yellow and snake gallbladder were screened out to inhibit viral gene expression, which solved the shortcomings in the antiviral mechanism of traditional Chinese medicine, achieved effective inhibition of multiple viruses, and provided New drug development ideas.
Patent Information
- Application Number
- CN202411014734.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
There is a lack of existing traditional Chinese medicines such as beef yellow, snake gall, Panax notoginseng and musk in the research on antiviral mechanisms, and there is a lack of sufficient modern drug research, especially the efficacy mechanism of their drug has not been fully explained, making it difficult to develop effective antiviral drugs.
Potential broad-spectrum antiviral small RNAs were screened through high-throughput sequencing technology, and overexpression plasmids were constructed to express sRNAs with broad-spectrum antiviral effects, combined with recombinant expression vectors, and used to prepare antiviral drugs, specifically including from beef and The sRNA sequence was screened out from snake gallbladder, and the nh-1 and sd-1 plasmids were constructed to inhibit viral gene expression.
It has achieved inhibition of the expression of multiple viral genes at the cellular level, provided new research ideas on pharmacological mechanisms of traditional Chinese medicine, and demonstrated that it has medicinal value for infection of multiple viruses, and its effect is better than that of the existing drug Ribavirin.
Smart Images

Figure CN118931902A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biopharmaceutical technology, and specifically to the application of sRNA derived from traditional Chinese medicine and its vector in the preparation of broad-spectrum antiviral drugs. Background Art
[0003] At present, the mechanisms of action of commonly used antiviral drugs include preventing virus adsorption, entry into host cells, inhibiting the replication, transcription and translation of viral nucleic acids, and interfering with the release of viruses from host cells.
[0004] There are many traditional Chinese medicines and Chinese patent medicines in my country that have antiviral effects or relieve the symptoms caused by viruses to the human body, mainly some medicines with heat-clearing and detoxifying effects, such as honeysuckle, isatis root, Lianhua Qingwen capsule, etc. Similar to most traditional Chinese medicines, there is a lack of research on the mechanism of its efficacy, and its therapeutic targets and mechanisms of action need to be further clarified. In recent years, the study of MIR2911 in honeysuckle has shown that small RNAs in traditional Chinese medicines may be effective antiviral active substances.
[0005] MIR2911 was first discovered in honeysuckle in 2015. It is a natural functional small molecule that can regulate target genes in non-plant bodies and inhibit a variety of viruses. It is a new type of nucleic acid active ingredient with broad-spectrum antiviral potential.
[0006] Its antiviral mechanism is as follows: exogenous MIR2911 is transported to cells through the SIDT1 protein of gastric apical cells in the gastric mucosa, and then enters the circulatory system to exert its effects; its sequence is GGCCGGGGGACGGGCUGGGA, which is a high GC sequence in base composition. Almost all viral genomes contain 60% high GC sequences. MIR2911 binds to viral target mRNA through base pairing to inhibit viral gene expression. Current studies have found that MIR2911 can target 94% of known viruses. However, there are only 10% high GC sequences in the human genome, so safety is guaranteed.
[0007] Bezoar, snake gallbladder, Panax notoginseng, and musk are common Chinese medicinal materials. Bezoar is a stone in the gallbladder, bile duct or liver duct of cattle or buffalo, which can be used to relieve fever, detoxify and calm nerves; snake gallbladder is the gallbladder of the black wind snake or other snakes of the colubrid family, which is cool in nature, bitter and slightly sweet in taste, and has the effects of clearing heat and detoxifying, resolving phlegm and relieving spasm; Panax notoginseng is the dried root of Panax notoginseng of the Araliaceae family, which has the effects of removing blood stasis and stopping bleeding, promoting blood circulation and relieving pain; musk is the dried secretion in the scent sac of mature male deer, which has the effects of opening the mind, refreshing the mind, promoting blood circulation and menstruation, and reducing swelling and relieving pain.
[0008] Similar to most traditional Chinese medicines, bezoar, snake gall, Panax notoginseng, and musk also suffer from the defect of lack of sufficient modern drug research, that is, there is a lack of research on the mechanism of their efficacy, and their therapeutic targets and mechanisms of action need to be further clarified. Summary of the invention
[0009] In view of the above-mentioned technical limitations, the present invention selects four traditional Chinese medicines, namely bezoar, snake gall, Panax notoginseng and musk, for high-throughput sequencing, screens out potential broad-spectrum antiviral small RNAs through bioinformatics technology, constructs a broad-spectrum antiviral overexpression plasmid, further studies its antiviral mechanism and effect, and then proposes the application of sRNA derived from traditional Chinese medicine and its vector in the preparation of broad-spectrum antiviral drugs; it overcomes the shortcomings and defects mentioned in the background technology.
[0010] To achieve the above objectives, this application adopts the following technical solutions:
[0011] The invention of the present application is to provide an sRNA, which is an sRNA comprising a nucleotide sequence as shown in SEQ ID No.1 and / or SEQ ID No.2.
[0012] The sRNA sequence shown in SEQ ID No. 1 is derived from bezoar, and the sRNA sequence shown in SEQ ID No. 2 is derived from snake gall.
[0013] SEQ ID No.1:
[0014] GGGUCGUUAGCUCAGUUGGUAGAGCAGU.
[0015] SEQ ID No.2:
[0016] GUUUCUGUAGUGUAGUGGUUAUCACGUUCG.
[0017] Optionally, the above-mentioned sRNA contains 2'-fluoro-modified, 2'-methoxyethyl-modified, 2'-deoxy-modified, 2'-amino-modified, 2'-O-allyl-modified, 2'-C-alkyl-modified, 2'-hydroxyl-modified or 2'-O-alkyl-modified nucleotides.
[0018] The second invention point of the present application is to provide a recombinant expression vector, which can transcribe the above-mentioned sRNA.
[0019] Optionally, the above-mentioned recombinant expression vector is a plasmid vector.
[0020] The plasmid expressing the sRNA of the sequence shown in SEQ ID No. 1 was named nh-1.
[0021] The plasmid expressing the sRNA sequence shown in SEQ ID No. 2 was named sd-1;
[0022] The third invention of the present application is to provide a host cell, wherein the host cell contains the above-mentioned recombinant expression vector.
[0023] Optionally, the host cell is a BHK-21 cell or a Neuro-2a cell.
[0024] The fourth invention point of the present application is to provide a pharmaceutical composition, comprising the above-mentioned sRNA, the above-mentioned recombinant expression vector, and pharmaceutically acceptable excipients.
[0025] Optionally, the pharmaceutical composition described above is selected as a pharmaceutical dosage form suitable for oral, intravenous, subcutaneous, transdermal, intramuscular, intraarterial, intraperitoneal, intrapulmonary, intracerebrospinal, intraarticular, intrasynovial, intrathecal, intraventricular or inhalation administration.
[0026] The fifth invention point of the present application is to provide the use of the above-mentioned sRNA, the above-mentioned recombinant expression vector and the above-mentioned pharmaceutical composition in the preparation of broad-spectrum antiviral drugs.
[0027] Optionally, in the above application, the virus is a virus having an NS3 gene; preferably Japanese encephalitis virus and / or dengue virus.
[0028] The broad-spectrum antiviral mechanism of the sRNA, plasmid, etc. provided in the present application is to express sRNA to complement and pair with viral genes, thereby inhibiting the expression of viral genes.
[0029] Compared with the prior art, this application has the following advantages:
[0030] The present application detected two sRNAs from bezoar and snake gall by high-throughput sequencing technology, and constructed two plasmids expressing sRNAs, which can inhibit the expression of multiple viral genes at the cellular level and have medicinal value in combating infection by multiple viruses; and this technology provides a new idea for the study of the pharmacological mechanisms of traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Shown is the number of potential broad-spectrum antiviral small RNA targeting viruses contained in bezoar, snake gall, Panax notoginseng, and musk in one embodiment of the present application.
[0032] Figure 2 Shown is the electrophoresis result of the inhibitory effect of plasmid sd-1 or nh-1 on the expression of JEV-NS3 in one embodiment of the present application.
[0033] Figure 3 Show this application Figure 2Figure 3. Quantitative analysis of JEV-NS3 expression by plasmid sd-1 or nh-1 in WB assay.
[0034] Figure 4 Shown is the electrophoresis result of the inhibitory effect of plasmid sd-1 or nh-1 on DENV-NS3 expression in one embodiment of the present application.
[0035] Figure 5 Show this application Figure 4 Figure 3. Quantitative analysis of DENV-NS3 expression by plasmid sd-1 or nh-1 in WB assay.
[0036] Figure 6 It is shown in one embodiment of the present application, that is, the effect of plasmid sd-1 or nh-1 on the body weight of mice infected with JEV. DETAILED DESCRIPTION
[0037] In order to make the purpose, technical solution and advantages of the present application more clear, the present application is further described in detail below. However, it should be understood that the description here is only used to explain the present application and is not used to limit the scope of the present application.
[0038] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present application, and the terms used herein in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application. The reagents and instruments used herein are all commercially available, and the characterization means involved can refer to the relevant descriptions in the prior art, which will not be repeated herein.
[0039] In order to further understand the present application, the present application is further described in detail below in conjunction with the best embodiment.
[0040] Example 1
[0041] Sequencing of sRNA of bezoar, snake gall, Panax notoginseng and musk:
[0042] Sequencing was performed using the Illumina Hiseq6000 platform. Total RNA was extracted from the above four traditional Chinese medicines, and 18-30 nt RNA was separated by PAGE electrophoresis. The sRNA library was constructed, including connectors, cDNA synthesis, and PCR amplification for library enrichment. PAGE electrophoresis was used to separate 100-120 bp PCR products, which were the library fragments constructed by sRNA. Finally, the constructed library was quantified, pooled into a circle, and quality tested. After the quality was qualified, it was sequenced on the machine.
[0043] After sequencing is completed, the data processing of the sequencing results is completed by removing the adapters, removing low-quality and contamination processes to obtain a reliable target sequence for standby analysis. The cleaned target sequence is classified and annotated to obtain the sRNA components and expression level information contained in the sample.
[0044] Example 2
[0045] Predict the number of targeted viruses of candidate sRNAs and screen for broad-spectrum antiviral sRNAs:
[0046] The number of viruses targeted by candidate sRNAs was predicted. Known viral genome sequences were downloaded from the NCBI Genome database (https: / / www.ncbi.nlm.nih.gov / genomes). The RNAhybrid software was used to calculate the binding sites of potential sRNA sequences on each virus (parameters: -e-20-u 6-v 6-f 2, 8), and the number of viruses that each sRNA sequence might target was counted.
[0047] like Figure 1 As shown, the present application screened out a variety of sRNAs with potential antiviral effects targeting more than 2500 viruses from bezoar, snake gallbladder, Panax notoginseng and musk. One of the sRNAs used is niuhuang_39_30035, which has the largest number of targeted viruses in bezoar, and the constructed plasmid is named nh-1; the other sRNA is shedan_20_94082, which has the largest number of targeted viruses in snake gallbladder, and the constructed plasmid is named sd-1.
[0048] Example 3
[0049] Design and preparation of plasmid sd-1 and plasmid nh-1:
[0050] Both plasmids are sRNA overexpression plasmids. The plasmid system uses CMV as a promoter and pre-miR-155 as a basic skeleton.
[0051] The sd-1 plasmid is a plasmid in which a DNA sequence expressing sRNA (5'-GTTTCTGTAGTGTAGTGGTTATCACGTTCG-3'), a loop stem-loop sequence (SEQ ID No.3: 5'-GTTTTGGCCACTGACTGAC-3') and a sequence complementary to the DNA sequence expressing sRNA (SEQ ID No.4: 5'-CGAATGATAAACTACACTACAGAAAC-3') are inserted into the backbone. The overall sequence is shown in SEQ ID No.6: GTTTCTGTAGTGTAGTGGTTATCACGTTCG-GTTTTGGCCACTGACTGAC-CGAATGATAAACTACACTACAGAAAC according to the arrangement of DNA sequence expressing sRNA-Loop sequence-complementary sequence: GTTTCTGTAGTGTAGTGGTTATCACGTTCG-GTTTTGGCCACTGACTGAC-CGAATGATAAACTACACTACAGAAAC.
[0052] The nh-1 plasmid is a DNA sequence expressing its sRNA (5'-GGGTCGTTAGCTCAGTTGGTAGAGCAGT-3'), a loop stem-loop sequence (SEQ ID No.3: 5'-GTTTTGGCCACTGACTGAC-3') and a complementary sequence of the DNA sequence expressing sRNA (SEQ ID No.5: 5'-ACTTCTACCAACTGATAACGACCC-3') inserted into the backbone. The overall sequence is shown in SEQ ID No.7: GGGTCGTTAGCTCAGTTGGTAGAGCAGT-GTTTTGGCCACTGACTGAC-ACTTCTACCAACTGATAACGACCC according to the arrangement of DNA sequence expressing sRNA-Loop sequence-complementary sequence: GGGTCGTTAGCTCAGTTGGTAGAGCAGT-GTTTTGGCCACTGACTGAC-ACTTCTACCAACTGATAACGACCC.
[0053] After the plasmid is transfected into cells or tissues, it can produce a large amount of sRNA to exert an antiviral effect.
[0054] Example 4
[0055] Examples of plasmids SD-1 and NH-1 against JEV virus:
[0056] In order to illustrate the broad-spectrum antiviral effect of plasmids sd-1 and nh-1, this embodiment studies the anti-JEV effect of the two plasmids at the cellular level. Neuro-2a cells were divided into 6 groups, which were set as a healthy group (mock), a blank control group (CV) infected with viruses, a negative control group transfected with ncRNA, a positive drug group (Ribavirin), a transfected sd-1 group and a nh-1 group. In addition, Neuro-2a-pre means that the drug is administered before infection with JEV virus to study the preventive effect of sd-1 and nh-1 on JEV, and Neuro-2a-post means that the drug is administered after infection with JEV virus to study the therapeutic effect of sd-1 and nh-1 on JEV.
[0057] like Figure 2 , Figure 3 As shown in the results, both plasmids can inhibit the expression of JEV-NS3 protein at the protein level, whether administered before or after JEV infection, and the effect is stronger than that of the positive drug Ribavirin. The above results show that sd-1 and nh-1 may play a certain positive role in the prevention and treatment of JEV by reducing the expression of JEV-NS3 protein.
[0058] In addition, this example was also verified on BHK-21 cells, which also confirmed that the two plasmids can inhibit the expression of JEV-NS3 protein, and the reduction degree of the two plasmids is similar.
[0059] Example 5
[0060] Examples of plasmids SD-1 and NH-1 against DENV virus:
[0061] The preparation process of plasmids sd-1 and nh-1 is the same as that in Example 3.
[0062] In order to illustrate the broad-spectrum antiviral effect of plasmids sd-1 and nh-1, this example studies the anti-DENV effect of the two plasmids at the cellular level. BHK-21 cells were divided into 6 groups, namely a healthy group (mock), a blank control group infected with virus (CV), a negative control group transfected with ncRNA, a positive drug group (Ribavirin), and a transfected sd-1 group and nh-1 group. Figure 4 , Figure 5 As shown, both plasmids can inhibit the expression of DENV-NS3 protein, and the effect is stronger than that of the positive drug Ribavirin, which is consistent with the results in Example 4.
[0063] Example 6
[0064] Effects of plasmids sd-1 and nh-1 against JEV in mice:
[0065] Prepare 50 6-week-old female C57BL / 6J mice and 4 After each mouse was inoculated with JEV virus, PBS, ncRNA, Ribavirin, sd-1 and nh-1 were injected into the mice through the tail vein on the first day, once every two days, for a total of 3 injections in 5 days. After that, the weight of the mice was monitored every day, and the number of surviving mice in each group was recorded after 15 days.
[0066] like Figure 6 As shown, the results showed that after virus inoculation, the weight of mice treated with PBS and ncRNA decreased significantly, Ribavirin treatment slightly improved the weight loss symptoms of mice, and sd-1 and nh-1 treatment could significantly improve the weight loss of mice caused by JEV infection. At 15 days, all mice in the PBS and ncRNA injection groups died, and the number of mice that survived after injection of Ribavirin, sd-1 and nh-1 was 3, 4, and 5, respectively, indicating that sd-1 and nh-1 treatment can increase the survival rate of mice, and the effect is stronger than Ribavirin. This shows that plasmids sd-1 and nh-1 also play an anti-JEV virus role in mice.
[0067] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims
1. An sRNA, characterized in that It is an sRNA comprising the nucleotide sequence shown in SEQ ID No.1 and / or SEQ ID No.
2.
2. The sRNA according to claim 1, characterized in that The sRNA contains 2'-fluoro-modified, 2'-methoxyethyl-modified, 2'-deoxy-modified, 2'-amino-modified, 2'-O-allyl-modified, 2'-C-alkyl-modified, 2'-hydroxy-modified or 2'-O-alkyl-modified nucleotides.
3. A recombinant expression vector, which is capable of transcribing the sRNA according to claim 1 or 2.
4. The recombinant expression vector according to claim 3, characterized in that The recombinant expression vector is a plasmid vector.
5. A host cell, comprising the recombinant expression vector according to claim 3 or 4.
6. The host cell according to claim 5, characterized in that The host cell is a BHK-21 cell or a Neuro-2a cell.
7. A pharmaceutical composition comprising the sRNA according to any one of claims 1 or 2 and the recombinant expression vector according to any one of claims 3 or 4, and further comprising a pharmaceutically acceptable excipient.
8. The pharmaceutical composition according to claim 7, characterized in that The pharmaceutical composition is selected to be in a pharmaceutical dosage form suitable for oral, intravenous, subcutaneous, transdermal, intramuscular, intraarterial, intraperitoneal, intrapulmonary, intracerebrospinal, intraarticular, intrasynovial, intrathecal, intraventricular or inhalation administration.
9. Use of the sRNA according to claim 1 or 2, the recombinant expression vector according to claim 3 or 4, and the pharmaceutical composition according to claim 7 or 8 in the preparation of a broad-spectrum antiviral drug.
10. The use according to claim 9, characterized in that: The virus is a virus having NS3 gene; preferably Japanese encephalitis virus and / or dengue virus.
